0000950103-11-005177.txt : 20111208 0000950103-11-005177.hdr.sgml : 20111208 20111207184727 ACCESSION NUMBER: 0000950103-11-005177 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20111207 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20111208 DATE AS OF CHANGE: 20111207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS CAREMARK CORP CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 111249602 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 FORMER COMPANY: FORMER CONFORMED NAME: MELVILLE CORP DATE OF NAME CHANGE: 19920703 8-K 1 dp27619_8k.htm FORM 8-K
 
 




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
 


FORM 8-K
 
CURRENT REPORT
Pursuant To Section 13 Or 15(d) of The Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  December 7, 2011
 
CVS CAREMARK CORPORATION
(Exact name of registrant
as specified in charter)
     
     
 
Delaware
001-01011
05-0494040
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
One CVS Drive, Woonsocket, Rhode Island 02895
(Address of principal executive offices)
 
     
Registrant’s telephone number, including area code:  (401) 765-1500
 
(Former name or former address, if changed since last report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 


 
 
Item 8.01. 
Other Events.

On December 7, 2011, CVS Caremark Corporation, a Delaware corporation (the “Company”), issued a press release announcing the expiration and final results of its tender offer for any and all of its 6.302% Enhanced Capital Advantaged Preferred Securities.  A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01    
Financial Statements and Exhibits

(d)  Exhibits
 
 
Exhibit  No. 
Description

99.1 
Press release, dated December 7, 2011, of CVS Caremark Corporation

 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   
CVS CAREMARK CORPORATION
 
       
Date:
December 7, 2011
 
By:
/s/ David M. Denton
 
       
Name:
David M. Denton
 
       
Title:
Executive Vice President and Chief Financial Officer
 

 
 

 
EX-99.1 2 dp27619_ex9901.htm EXHIBIT 99.1
 
 
Exhibit 99.1
     
Investor Contact:
Nancy Christal
Senior Vice President
Investor Relations
(914) 722-4704
Media Contact:
Eileen H. Boone
Senior Vice President
Corporate Communications & Community Relations
(401) 770-4561


FOR IMMEDIATE RELEASE
 
CVS Caremark Corporation Announces Expiration of Cash Tender Offer
for its 6.302% Enhanced Capital Advantaged Preferred Securities
(CUSIP NO. 126650BK 5)
 
WOONSOCKET, RI, December 7, 2011 – CVS Caremark Corporation (NYSE:CVS) announced today the expiration and final results of its previously announced tender offer (the “Tender Offer”) as of 5:00 p.m., New York City time on December 7, 2011 for any and all of its $1,000,000,000 outstanding 6.302% Enhanced Capital Advantaged Preferred Securities (the “Notes”).

The Tender Offer commenced on November 29, 2011 and expired at 5:00 p.m., New York City time, on December 7, 2011 (the “Expiration Date”).  Based on the final tabulation provided by the Information Agent for the Tender Offer, D.F. King & Co., Inc., holders of the Notes tendered $957,715,000 aggregate principal amount of the Notes on or prior to the Expiration Date.

The settlement date for Notes validly tendered on or prior to the Expiration Date is expected to be December 8, 2011. In addition to the Total Consideration, holders of Notes accepted for purchase will receive accrued and unpaid interest on those Notes from the last interest payment date with respect to the Notes to, but not including, the settlement date.
 
For a complete statement of the terms and conditions of the Tender Offer, holders of the Notes should refer to the Offer to Purchase and the Letter of Transmittal dated November 29, 2011.  Copies of the Offer to Purchase and Letter of Transmittal may be obtained from D.F. King & Co., Inc. at (212) 269-5550 (for banks and brokers only) or (800) 949-2583 (for all others toll-free).
 
Barclays Capital Inc. and Deutsche Bank Securities Inc. acted as the Dealer Managers for the Tender Offer. 
 
About the Company:
 
CVS Caremark is the largest pharmacy health care provider in the United States with integrated offerings across the entire spectrum of pharmacy care. We are uniquely positioned to engage plan members in behaviors that improve their health and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country’s largest pharmacy benefits managers (PBMs), we provide access to a network of approximately 65,000 pharmacies, including more than 7,300 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical offerings include our signature Pharmacy Advisor™ program as well as innovative generic step therapy and genetic benefit management programs that promote more cost effective and healthier behaviors and improve health care outcomes. General information about CVS Caremark is available through the Company’s website at http://info.cvscaremark.com.
 
 
 
 

 

Forward-looking Statements:

This press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010 and under the section entitled “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Quarterly Report on Form 10-Q.
 
 
 

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@," M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$! M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,` M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`$$`D`,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/W\H`*`"@`H`*`"@`H`*`"@`HV\K`8H\2>'?M'V-=>T7[6& MV_91JEC]H##^'R!/OW<]-O>LO;T.;E5:',NG/&_W7N=_]E9HJ7MO[-Q2HVNI M_5ZJA;OSF=IXHNNC&X2C:\7'M=-`TD<>-[I&.VY@OY9(IZ+R%&,G\,6[=E_ MD"R1L"5D1@HRQ5U(4'/)(/`X/Y4DUT>PW"4;)Q<7TNFON,?_`(27PX)_L@U_ M1!<[MOV;^U;`3[C_``^3Y^_=STQ6?MZ"?*JU-273GC?[KG=_9.:JG[;^S,6J M-K\_U>MR6[\W)RV\[FT,=NG;%:^AY^VFQ5:_L4OHM,:]M%U*:TGOX-.:XA6^ MEL;6:WM[F]BM"_FO:0W%Y:123*A1'NH58AI%#3SP4U3YDJEG)1NE+E32*=8\`>' M=2N=+\)>'+F73=4-C.]M-X@U6W.W4/M<\+ACIEM.K0)`K!9'ADDDW`HJ?GW$ M&;UJV(JX*A4=+#4&X2Y79U)KXKM?8B]%'9V;=]+?V)X/^'.795DV!XES3"0Q M>=9I3C7PZJP4XX+#U-:/LH232KUH-5)U&N:$91A#E:FY>:P_LR?%27P0OCZ/ M1-.%@VGG68]):\V>)&TP1&Y%\M@;81[FM_WRP_:!.5(Q'O(6N%9!F'U3ZXJ4 M>3EYU#FM5Y+7YN6UM5JESCC*U3#5,OG4OF/#669=G>#XNPF#IX#&8>3PV8NG3C"GB\%BFJ4 MY5X**@ZV'K.C7A5LI.,)QFY+EMZA^R)XK?0_C!8Z=-<2?9/%NCZCHI$DKLAN MX475K!@&8@.6LIHP?^G@CO7?PUB'1S.%-R:CB82A9O[2]^/_`*2U\SX_QOR6 M./X&Q&*I48JOD>*HXI^//#GA6VN M)%@\-Z"U_=1Q2/&%U#7;C+<8X>GS-) MVM*H_+^[%?>>%]'_`":.%X;S7.*M*/M,TQBHTW**?[G"0MI=:)UJU1.V[AY' MS)=:[XI\/^&K?PG#?WVEZ9XBBM?%.J0V]Q/!-K,5[&T.D)?2JXDDL(K.$RQV M^[RRUX\C*6(V^"ZV(H4(X:,I4H5DJLTFTYJ2M#FV;BHJZCM>5WY?KM'+\21R1M<3>&=%N)KOQ3:!9S"8I+-+;8VH*P+M;"02!1E= MQ(!ZZ628JK@EC,,Z=96NZ5-MU5K:W*E;FZVNG;NSYW'>*.0Y3Q-4X8S>GC[&KR.#EHU%79]6?LJ77QE\-:U<^"O&_A?Q MI;^#[G3I[K2+[Q!IE^EOH.I6C1N;.*]NU_%/$T<%7HN>+H5%)>UE1I-G_P`C;#_]@F(_]/88_),/_P`F]S?_`+*+*/\`U6YV>K5Z)\8% M`!0`4`%`!0`4`%`!_GTH_`-OD?@KXFBDMO&7B.'5%*R0>+M9745DSN`37+G[ M4'SW\L/FOQ_$)QQ5=5-+5I\WRJ.Y_I%E$H3R'*IX)KDGEN%=!QVUPE/V=OG8 M_=B&XT]='BNE>$:4NFI<"0[3;C3Q:B4.<94P_9N>X*^U?KB=+%/'3HLZ3IFA M0^%'UG4M0M;'25M?`L]O/)?WDJP6RP7`T-/)=I)`!)O4#=G('->%1S#A^=6G M3HQH^TE)1@HX=I\TM%9\BM=O<_6,PX+\8,%@,;B\PGF,,!A*-2MB74S>$X1H MTXN=1SA];ES)13;CRMO:S9^>>OZ==?!OXUSVT(>+_A#/&]IJ.GLPVF31A?0: MC8L,_P`$FD3K&3R/O=<&OBZU.65YJXQT^J5U*/\`@YE-??!V/Z?RS%4>.?#^ ME5G9_P!O935H5DM>7%>RG0J_.&)@Y+KMW'>-[ZX^,'QJU9](D>X'C'QA;Z/H MDA!4C2_.@TG3IMIY15T^!9R#T&[THQS36]K7/Y[\.O%G%\/SQ^%SW M+\3C\KS3&5LT"S-XD\.7S7&GQQDCRYWU30[EO)A/!#3^6,8)`&*^3K9=F> M7?O94:E&,-?:4I7BO/GIO1>MC^A,MXSX%XN4UV?3'[,G[0WC34_&&F_#OQKJ,OB.QUN.ZBT?5KT*VL:?J% MI:37JP7-VB@ZA9SP6\Z[IPTJ.J'S"I85[V0YUBIXJG@L54=>%5-0G+XXR2&/^R4^.?_`%+OAW7TT_\`D;8?_L$Q'_I[ M#'X9A_\`DWN;_P#9191_ZK<[/5NGX?UKT3XS\`_SZ4;!L%`!0`4`%`!0`4`% M`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`-/88_"\/_R;W-_^RBRC_P!5N=GE/QB^./B+2O&6D_"#X465EJ/Q!UA[=+S4 M=07S=.\.I=Q&YB#0_=FNUL5:\E:4-%!!M9DE>0(OG9GFU>EBJ669=",L;4:O M*7PTKJZTZR4?>=](QZ-NQ]EP)X>97BLAQO''&>(JX3AC`*=]D+?+YBQJP!W",'Y:M9=F\8\_]M2]OORNC#V5^UM[>=K];'//C/PXE M7^K?\0PHPRJ_+[6.98J./4-N=2O[/VEM>1R<6_=<[:GH=]XR\1^`?A#/XS^( M%GIMSXGT#0OMNNV&EW'V+3[O4A.(([6RN"ESY33M)"BL$=3))PJJ<+VSQ5?! M98\5C(1>(H4^:I&#Y8N5[)1?O6O=='J^B/E\-D.5<2<<4\@X8KUZ&49EC/98 M.MB(>UK4J#ASNI5@G2YE32G)KFC+D6KE)7?.?`WX\Z;\:(_$"1:%+X:U'0); M(OIT^IQZD]S97R2^7>QR1V=ML5;B":)T*':0AW?.`,,ISBGF:K)4?J]2@XWB MY*5U*]I)I1ZIIJWYGJ^(?AOBN`)99*>8QS7"YG&KRUH4)8=4ZM)QYJ4HNK5N MY0G&<9YVY'X:8?->"<3QK7XA>"PF!]O[?#0P#KU8^PG&+Y)?6Z,9\RJ0DDU"UV MGM=YOC+]HW4_AKXPT#PMX\^'3:7:Z^]NUOKVC^*H-:M%M)KI+*6Y2U?1+.61 M[>XD3S86,3!'#IO!4-&)SNI@,31P^,P/LXU;6J0JJ<>5OE;MR1=XMZK1VU5S MKR'PKPG%619EG'#7%"Q=;+%-3P>)RZ>$J.I"FZL8.HL77A%58)^SJ+GBY)QE MRV=MCXJ_'J[^&7C;PSX+3P5_;TGBV*S.D:B/$<6E0_:KK4?[,:VNH'TBX,*Q MSO`YE5W!28';E2*TS#.)9=B\/A%A/:O$*/)+VG(KN7+:2Y)6LVM4WHS@X,\- MJ'%O#^;9\\__`+,ADDJOUFA]1EB)>SIT/K"G3G'$TE)R@II0<8M2C:]FF==+ MXY^(.E:[X8TW7?AE;6VD>(=632)]>T7QDNM0Z)--;SS02ZA8R>&[*7R))(?) M613LWR(&=2ZANEXO&TJV'IU<`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`TUA%8W%M+"[NC0_)/.K#)!PA`!!S'$.8XS+5A98 M2<8*ISJ2E!2UBHM6VMN[]]#H\&^"N&N,ZF>X;/<-7J5,`L)4H3HXB="T:TJL M*D9**:EK&#B[)KWKW35F_$C7_C5X+^%<'Q*TGX@Z1J/E:?H6HZII6H>"],MU M2WUHV4):QN;:[SYD-S?0_)*C;TW'<&'S&.K9KA,OCCJ6-A/EC3E.$J$595.5 M>ZU+HY+1K5=1\*99P!GO&53A/&<,8G!\];%T,/B*&:UYMSPOM9VJTYT[6J4Z M4O>A)ZT[J7P]^T1KB?`*V^+6L>%HM9O]-UAM#UZUL+_^Q89E34%TU-9L MQ+:W85'FGM`\'0,\A1MJA:=#.ZJR:.8U,.JDZ<_9U(QER+XN7GCI*UVU==V[ M/2Q&9^%V7/Q*J\%8#.)9?AL5AEB\'4JT?K4H-T77>%J\M2@VXQA5<:F[BH_9+=?/E, M(Q''$QW2HB[W.#ZF'Q\*N7QS"K%8:FX.HTYW48INUY6CJ[;);NVK/@\ZX0Q& M6\85N#LNJU,WQE+$T\+&=/#NE*K5G&$I>SH^UJ/ECS.\I32M&4YHLFBF_UL7^I:K`Q^6^%@FDVWV.P=>8WEDWR`AECV M$.RR[&U\;15>>#^J4I:PYJG-*:_FY>2/+%]&W=[I6U-.-.&X_#MQQ7L<)[&AAIK>C[9XFK[6M%Z3C"')!WBY\Z<4Z]_P"2X>&/^R4^.?\` MU+OAW1+_`)&V'_[!,1_Z>PPL/_R;W-_^RBRC_P!5N=GQ9\)IXY/VR?&SZDS? M:SK7Q+@T\R\'S+>]EM[55#'.1HL#JF/^6:\<5\MEK7^L^+Y_B]IBE&^FTFE_ MY(G;R/WSC6G*GX$`(;'5=53Q#XQL_$/B#3-"L9M4U27PKX-EAU2^5 M-.M_GGBEOGL%/&/W;$],'P,\J7>`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`J>:_P`J;MS<`U7$7,LURGDCS2NK1NE=^UC97>BOW>B.?P9] MBN`/$%5ZOU:A:HJE7DE4]E!Y?64JGLX^]/D5YE:RU9]2Z'XO^(>H>/;3 M0M?\!'PEX;D\.ZIJ,.H-K%AKSZAJMM>Z9#'9M-IH$6F^7;7,\OEN6:;.Y2!$ MPKZ"CB<;+&1HU<']5H>RG)2YXU'*:E!*-X:0LFW9ZR^1^/9CD?"^$X;K9CE? M$G]M9K#'8>A*@L+6P<:&'J4L1)U5"N^>OSSA"'/%*-+:2;G%GY^?&?P,NI7_ M`,>/&U@DJ:CX.^*FBQ7,D9/RZ/K>CP+)-_L-!K#V4H;L)&Z8&?C`>(7@L-X< M?;:?IVLW@7DJ-2A/\6:Z\=B5F>!57>.!PBJ5/+$U9*FD_.,8SE_V\CYOA7(Y M<`<5SR]1]E6XIXAG@\'=).628&A4QM2<.O)6K5\+0;TYG0J+H=-X'\377AC] MCB>32Q*VN:Y=:YX4T""W1GN;C6/$NO7.E6T5K&GS/<".XGE15!),/'-=&$KR MPW##]FG[6JZE&FENYU:C@K)=;-M>AY'$.44$S'&3FU&G# M#8'!PQ$Y5&](P$YRXMR+C7AO-GQ9.,\+E\X/W)RG*/HZ::?W:GPGT>\-7P.?\7X.O#V> M(PE'#T:D'IRU*>+G"<7Z233.#^*OQ%\97T'@/X1?$.SL?`G@#5;+PC=WOB;0 MS=:M/JV@1VUF8+R*:[2".**VN5B:Y@$+/$\89O,C51/R9CC<5)8/+,9&.#P= M2-%NK3O)SIVC[R^'_@_P",O@KX M,M]16Y\'Z1X3O)DAT^YN-,M["^U_1+Z"_O=>4&VDN;\W9EW%]\LLK80#.WT, MVK8*AEF)RG"1DI8:%&32BW%1E4IR4I5/AO.]][R;V/C_``]ROB?,N.)S&E!RK4Z=>=:E@\71G1I8-M58T\-[/D:4>6G3BKR;M?P73O'TD=O\ M!O!WQ,T6\L/@]9Z=::D8DNA]D\47'VZ\BM]>U5K<'SM'T[47B,FEL0ZH'EE# M>9&*\>GC&HY/A<=2E#+(14K7LJKYI)5)VWA"5KT][7;W1^D8KAJ+J^)&>\(X M^E7XYK5ZE!2=-JIE\'1IRG@\.IVY,3BZ*ER8M7BYVIT[:-52ESJ=U-3N^;FOKS7OS7UO>^IY?>_\EP\,?\`9*?'/_J7?#NO/G_R-L/_ M`-@F(_\`3V&/L,/_`,F]S?\`[*+*/_5;G9\P?'KX)^.]'^(5O\:?A+;RWVIQ MW=GJ>J:/9(KZC;:K:1):OJ%I9.RC4["]M46.ZM5)D):5@KK*WE^!G&4XREC5 MFN6QI)U%1J54F\/6H5&Y8>LUR64(N4907/VWAG]H_XAZU;KIS_L_>.9 MO$RHL3+;++IN@M=$[3)<7^M64)TNU!(9O,,[*,X+8R>O#YYC:B]G_8N(]NM+ M*\:=^[E.*Y%ZW^9\_FWA5POEU1XJ/B9E%+*+N2YW&OC%3M?EA1PM6HL14MHN M54U)VTCL=!X%?Q5K7Q[\2:QXP\/W>G2:!\.](\.:/>P:=J2^&GO[B]AU3Q0N MB:I>0HMT%NY[>W$GRM,EDSJH487;"?6*F<5ZF)HNFZ.&A2A)1DJ7,Y*=7V)QV)HRKT/KT:,*4L/@'BL/2D MW3O3A.JXZJE*JHMN3N^3_;`^&FM>*M"\,>+?"FEW^I>(?#.I&SE@TBVFNM2; M2]19)8KF"&W5G;['J=M;R#:"5%S(W0$CFXFP%6O1P^(PU.4ZV'ERM03;4%5C+$U(4J"Q%!.,H3E-J*^L8>I M.#NTI.$8[M)^0/=>./$GQO\`@_\`$76?A_XUMH]-T7POIOBR2;PSJXBT[5[: M;6K'4;P;;3_CUWWEO>AE!VQS<\H:\SFQ=;-LLQU7!UX*$*4:S=*:4)ISC*6B MV]Y3TV3\C[B-'A[*/#WCGA7+^)LJG+%8K,*^6QCC\,I5L-4AA:U"EK55JEJ4 M\.TW[U2.FDD>B?M!?"+Q=HGC;1_C;\(;"YG\16U];OKVCZ7;F:XFNT`ACU:. MRBP;RVN[8FTU"$#+(RS8),K+W9SEN)HXNEFN60;K1DO:0@KMO9345\2DO=J+ MJO>UU9\MX9<;Y'CN'\=X?\;XBG1RNI2FL'B<1-0A"FWSRP\JLM*52C4_?X*H M](R3I725.+X_XN2^-_'WC'X*^/;+X;>.[-_#R6]QXGTE?#M_+>:->6/B"QO; MF&(-$JW<4D,4LEO(K?O$V[@C[E7FS)XO%XK*L9#`XB'L+.K#V"*?#W#.1%/AG\2)-6U;4;#3DO=?\)7FC:'HL-Y M=107.JZK=W$F3;VMN\DVR-6#F,*S(I+#WYYG4?)3PV`Q/M*DHQ3J490ITU*2 M3G-M[15W9;]T?D.%X%P6'^LXO..++-:_::T#Q/X:UO1=(\?ZS-)H5_JNE7-G; M7UBEOJ&C07EM-*@5Y8O(TVZ50IB*N?4,10J4:>-F_9RG!Q4 MHVE!--JUU:,E]Y]=Q/F^"R3`>$F99/FV$Q^-X9PL8XNCAL13J3HU7.CBI4IQ MBVU&?/7HR;5KIQ>IRV@?"#Q%X1_94\=:`^AWL_C?Q1]KO[W2;2V:749)(=6L M[*PM(H8QNE`TZQ%PH`Z73GN:YZ.65L+P[BZ'L9?6\1>4H15Y74XQBDO\,>;Y ML]C,N.,KSGQEX=S*.84J/#V3^SHTL14J*%",9X:K5K5)2>D;UZSI-O=TXKL8 MGPVT?Q-:6_[-_@S6?!OBO3].\/\`B;Q=XI\427.@:E%9V.M+<:K#X3^WR^1Y M<G'(\+5PM:$*%6M5JWIR48SO-4>9VM;7FOMLS MT.*\=E%6KXJY[E^>Y=B,5F>`RW+\OC3QE!U:N%<,/+,O8QYU)RM!4W"*N[32 MO>Q]+_M$>`Y_B#\*?$6DV%JUWK.FI%K^AP1(7FEU'26,QMH%`)::YLFN[95' M+-<`5[V=X-XS+J]*$>:K3M4II;N4-;+SDN:*76Y^2^%W$=/ACC/*\9B:RH8# M%.6#Q_BG3?BGXJ^$?@'P1>_#WQT=3\# MZOKL,#OX9U(IYAB,MP>$E@J_/A M)U$OW4]:517[_4WQMB\/>)?@5\/])UG1M2_X6!KEMX=TOP%HC6K M6GB*#Q8UI:6>H03V]RBR0:9&JRK>[U"&/RFX&%Y6YJ?.M8JI%_,_A[4KFR^%GQ;^!=]X;N8/B:VL:5> MVT%M;S7FL>)3IFMZ1]KTMMF][J;3;"V:XMA$3')9N\D0^1FD\*A.4,NS+*)T M'''\\)))-SJ\M2'-'2[;IQ5XVT<-5L[_`*WFF$HUN,>"?$7#9K3GPC'#8BE. M4YQHX7`?6,+B?9XA7Y8TXXNM45*NY)3ABE&%1^]%1^G/#/PD'Q3_`&:?#/@W MQ#I-]X:\6>&H=2@T:;6-.N+&[TS5K2]NS;N\-Q&LCZ5?6+&;9 M[E6,HYIDN:RH3Q,,+7A5IU\-4I4_:)2A)PCB,/5C.5*[3C)#_%.GRZ*)+;PUXEN-+NY]*ELK?<%TB\U:&-X,1*I^QW1DV2P M[(B5>-!+>18C'4(K+L=A:L'2TI57"3ARK[$IK33[$KV<;*]TK\OBMDW"N85' MQCPCGF7XF&.:J8[`0Q%*&(C5G:^)I8:3C4]]O_::*CS4ZMZB3C*?)[G=Z??' MXP^'M52SN#IEO\-?&.GS7ZQ-]DAO[OQ1X%N;6SDF`VI<36]E>2(A.66VD(X0 MUZ\H3_M.A44'[..%KQ:Y-XBT6RET_2K9]01M$L+2XMYK>YCM] M,:V*QO,+B61Y0XD+D'=A54<,LOHSQM/'RE4=>C%QA'F_=Q3332A;2][MWO?K MT/J\/QAF>$X6QG"%"AA*>5X^K&OB)QHM8JK4A.-2G*==33DHQ>/\`PM):23PZ-%(VJ:M96DH:SNK&*W4R7&KZ M?(3,,"I1QF':NH)\\XI^[**6\X/9*_-&\==$? MI'A'QU@-2,)8J26'PU6K&U2G5E-J-/#8I:3DW&-*LHU;Q MYIR7LWP<\>^(_&WAJ(^,?"'B3PAXKTQ(K?5X-9\/:MHUAJ,FTA=2T>>_M(HY MH9MI9[=6,D#DJR["COZF5XROBJ"^LX:KA<13LIJ=.=.,G_-!R233ZQWB]'I9 MOX/CKAO*N'%QN&Q-:A&]W0Q,*-6